These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 30838834

  • 1. Analytical and clinical performance evaluation of two POC tests for therapeutic drug monitoring of infliximab.
    Van den Bossche D, De Smet D, Debrabandere J, Vanpoucke H.
    Clin Chem Lab Med; 2019 May 27; 57(6):856-863. PubMed ID: 30838834
    [Abstract] [Full Text] [Related]

  • 2. Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease.
    Curci D, Lucafò M, Cifù A, Bramuzzo M, Martelossi S, Favretto D, De Pellegrin F, Fabris M, Vascotto F, Naviglio S, Ventura A, Stocco G, Decorti G.
    J Pediatr Gastroenterol Nutr; 2019 Oct 27; 69(4):474-479. PubMed ID: 31149938
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels.
    Novakovic V, Abdija S, Larsen PB, Fenger M, Gredal L, Jacobsen KK.
    Clin Biochem; 2019 Dec 27; 74():73-75. PubMed ID: 31669514
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits.
    Schmitz EM, van de Kerkhof D, Hamann D, van Dongen JL, Kuijper PH, Brunsveld L, Scharnhorst V, Broeren MA.
    Clin Chem Lab Med; 2016 Jul 01; 54(7):1211-9. PubMed ID: 26587745
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays.
    Afonso J, Lopes S, Gonçalves R, Caldeira P, Lago P, Tavares de Sousa H, Ramos J, Gonçalves AR, Ministro P, Rosa I, Vieira AI, Dias CC, Magro F, Portuguese IBD Study Group (GEDII).
    Aliment Pharmacol Ther; 2016 Oct 01; 44(7):684-92. PubMed ID: 27507790
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Infliximab trough levels: A comparison between the Quantum Blue Infliximab assay and the established ELISA.
    Lim MH, Aluzaite K, Schultz M, Casey P.
    J Gastroenterol Hepatol; 2020 Aug 01; 35(8):1302-1306. PubMed ID: 31881552
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease.
    Jukic T, Drobne D, Pusavec S, Ihan A, Stubljar D, Starc A.
    Med Sci Monit; 2023 Feb 18; 29():e939084. PubMed ID: 36807319
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of three immunoassays for infliximab trough level monitoring in paediatric inflammatory bowel diseases.
    Villemonteix J, Guérin-El Khourouj V, Hugot JP, Giardini C, Carcelain G, Martinez-Vinson C.
    Biologicals; 2021 Apr 18; 70():17-21. PubMed ID: 33676831
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies' Determination against ELISA.
    Toja-Camba FJ, García-Quintanilla L, Rodríguez-Martinez L, Tomine J, Cajade-Pascual F, Feitosa C, Zarra-Ferro I, Barreiro-De-Acosta M, González-López J, Mondelo-García C, Fernández-Ferreiro A.
    Pharmaceutics; 2023 Nov 11; 15(11):. PubMed ID: 38004593
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.